| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 |
| Sales | 497,730 | 451,670 | 546,850 | 515,270 | 555,810 |
| Sales Growth | +10.20% | -17.41% | +6.13% | -7.29% | +2.61% |
| Net Income | -2,441,480 | -28,480 | 23,440 | -3,280 | -243,540 |
| Net Income Growth | -8,472.61% | -221.50% | +814.63% | +98.65% | +66.28% |
Endo Int'l Plc (ENDPQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Endo International plc is a global specialty pharmaceutical company, which is focused on branded and generic pharmaceuticals. The four reportable business segments are: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. The Branded Pharmaceuticals segment consists of the company's legacy generics business together with the generic pharmaceuticals products obtained through the September 2015 acquisition of Par Pharmaceutical Holdings, Inc. (Par). The Sterile Injectables segment consists primarily of branded sterile injectable products such as Vasostrict, Adrenalin and Aplisol, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The Generic Pharmaceuticals portfolio includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics.
Fiscal Year End Date: 12/31